| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H17N3O8 |
| Molecular Weight | 319.268 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12O[C@@]3(O)O[C@]([H])([C@]4([H])[C@@H](O)N=C(N)N[C@]4([C@@H]1O)[C@@H]3O)[C@@]2(O)CO
InChI
InChIKey=CFMYXEVWODSLAX-QOZOJKKESA-N
InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3-,4-,5+,6-,7+,9+,10-,11+/m1/s1
| Molecular Formula | C11H17N3O8 |
| Molecular Weight | 319.268 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tetrodotoxin (TTX) is a potent marine neurotoxin that blocks voltage-gated sodium channels (VGSCs). VGSCs play a critical role in neuronal function under both physiological and pathological conditions. TTX has been extensively used to functionally characterize VGSCs, which can be classified as TTX-sensitive or TTX-resistant channels according to their sensitivity to this toxin. Wex Pharmaceuticals is investigating tetrodotoxin for the treatment of chronic and breakthrough pain. The toxin is currently undergoing Phase III clinical trials in Canada as a systemic analgesic for inadequately controlled pain due to advanced cancer, especially where the pain has neuropathic features. In addition, TTX is in Phase II clinical trials to study its ability in moderate to severe neuropathic pain caused by chemotherapy.
CNS Activity
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Tox targets
Sourcing
PubMed
Patents
Sample Use Guides
subcutaneous 30 µg twice daily for 4 days
intramuscular injection (1 ml volume), twice a day for four consecutive days.
Route of Administration:
Other
There was used micro-electrode array (MEA) recordings as an integrated measure of neurotransmission to demonstrate that tetrodotoxin inhibited neuronal electrical activity in both primary rat cortical cultures and human-induced pluripotent stem cell (hIPSC)-derived iCell® neurons in co-culture with hIPSC-derived iCell® astrocytes, with IC50 values of 7 and 10nM, respectively.
|
|
TARGET -> INHIBITOR |
IC50
7.8 NANOMOLAR (average) |
||
|
|
TARGET -> INHIBITOR |
4.5 NANOMOLAR (average) |
||
|
|
TARGET -> INHIBITOR |
IC50
2 NANOMOLAR (average) |
||
|
|
TARGET -> INHIBITOR |
IC50
5.9 NANOMOLAR (average) |
Showing 1 to 4 of 4 entries
